MeiraGTx (MGTX) Jefferies Global Healthcare Conference 2026 summary

Program Highlights, Pipeline Updates, and Strategic Partnerships

• Four late-stage programs are advancing, with two awaiting filing and two in or completing phase III trials, supported by major collaborations with Eli Lilly, Sanofi, and Hologen AI, securing over $335 million in upfront and equity investments, plus milestone and royalty opportunities.

• Collaborations include exclusive rights and first negotiation options for key technologies and indications, with Sanofi investing $60 million and Hologen AI providing $200 million upfront and $230 million for AAV-GAD commercialization.

• In-house GMP manufacturing supports rapid development, optimization, and commercial supply for viral vectors and plasmids, with scalable, flexible production processes.

• Commercial strategy targets concentrated KOL and patient populations for efficient market entry.

Xerostomia (Dry Mouth) Gene Therapy

• Late radiation-induced xerostomia is a severe, untreatable condition affecting 30-40% of head and neck cancer survivors, with 405,000 patients in major markets.

• Aquaporin-1 gene therapy (AAV-AQP1) shows durable, transformative effects in phase I, with three-year data demonstrating consistent patient benefit and improvements in patient-reported outcomes and saliva flow.

• Pivotal phase II study completed enrollment; 12-month data expected next year, with BLA filing targeted for late 2027 and launch in early 2028.

• Strong physician and payer buy-in, with high clinician preference due to a minimally invasive, outpatient procedure and strong safety profile.

X-linked Retinitis Pigmentosa (XLRP) Program

• XLRP gene therapy reacquired from Johnson & Johnson for $25 million, with key development team members joining.

• Completed the largest global IRD phase III study, showing statistically significant and clinically meaningful improvements in multiple vision domains, with 46% of treated patients achieving ≥10 letter gain in low luminance visual acuity versus 7% in controls.

• Regulatory filings planned for Europe, U.S., and Japan, with strong support from EMA and Japanese regulators and near-term BLA filings expected.

• Manufacturing capacity is established, with low cost of goods and commercial-ready drug supply.